Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 28;9:4965–4977. doi: 10.2147/DDDT.S77646

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Lipopolysaccharide (LPS)-induced increase of transcellular permeability was blocked by PP2 and MβCD.

Notes: (A) Absorbance of Evans Blue-labeled BSA (EBA) in the lower compartment of Transwell filter-grown pulmonary microvascular endothelial cells (PMVECs) after LPS treatment for indicated times. (B) Transendothelial electrical resistance (TER) changes of the monolayer PMVECs after LPS treatment for indicated times. (C) PP2 and MβCD pretreatment inhibited LPS-induced increase of EBA in the lower compartment of Transwell. PMVECs were pretreated with PP2 (15 μM) or MβCD (2 mM) for 15 min, and then treated with LPS (10 μg/mL) for another 15 min. The absorbance of EBA in the lower compartment of Transwell was determined. *P<0.05, **P<0.01 represent the index in LPS treatment group compared to the control group. ^##P<0.01 represents the index in LPS treatment group compared to the LPS treatment, PP2 and MβCD untreated group. This experiment was repeated for at least three times.